Company Overview and News
2018-09-25 investorplace - 2
Investing to “buy and hold” is trickier than it looks. The increasing pace of technological change means even the most successful, dominant companies have to continually adapt to keep up. Industries like energy, real estate and even consumer products are facing potentially significant long-term changes going forward. In any era, amassing a collection of retirement stocks simply by buying the best companies and holding them for years can be a risky endeavor.
FBHS BAC RSG MKC KO GM CAG DEO NEE MCD BUD GJT D WM MDT LW X BRK.A ALL IFF KODK
Property and casualty insurer The Allstate Corporation (ALL - Free Report) expects to incur $186 million, pre-tax ($147 million after-tax) catastrophe loss for the month of August. These losses can be attributed to 16 events at an estimated cost of $137 million, pre-tax. The rest of the loss pertains to unfavorable reserve reestimates of prior-reported catastrophe losses.
AT HIG HGH 8685 GJT AVF AIG EOG ALL ATP SRE SPG APRWF
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
ALL INO MDPEB DXC.WI MDP DXC
2018-09-15 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR
Chicago, IL –September 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Becton, Dickinson (BDX - Free Report) , Occidental Petroleum (OXY - Free Report) , Phillips 66 (PSX - Free Report) , Allstate (ALL - Free Report) and Deutsche Bank (DB - Free Report) .
WFC WFCNP DB CY PSX ALL MBUU OXY
2018-09-14 seekingalpha - 1
In this article, I'll review the most popular fixed-income securities, the fixed-rate preferred stocks, sorted into several categories. There are 366 issues in our database that trade on primary exchanges, excluding the convertible preferred stocks, half of which are part of the biggest ETF for fixed-income securities: iShares U.S. Preferred Stock ETF (PFF). As we can see in the chart below, half of the PFF's market capitalization consists of fixed-rate preferred stocks, which also corresponds to almost 60% of the fund's holdings.
PFF ALL GJT
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Becton, Dickinson (BDX), Occidental Petroleum (OXY) and Phillips 66 (PSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
DB PSX UMBF BRK.A COO ALL STI STI-A OXY
Sept 12 (Reuters) - U.S. insurers are bracing for what could be $20 billion in losses as Hurricane Florence barrels toward the Carolinas and Virginia, bringing punishing rains and potentially deadly flooding.
GJT TRV AVF AIG ZURVY ALL CB 8685 ZFSVF
After being blessed by a quieter catastrophe period, the second half of the year seems to be a different one for the insurers, with Hurricane Florence nearing Carolina coast as a Category 4 storm.
GJT AIZ AVF AIG NUE BRK.A ALL HIG BOE HGH BA 8685
Estimates for AXIS Capital Holdings Limited (AXS - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 move nearly 21.1% north to $4.77 and 1.2% for 2019 to $5.09. Shares of this Zacks Rank #3 (Hold) specialty lines insurance and treaty reinsurance service provider have gained 10.5% year to date, outperforming the industry’s growth of 7% and the Zacks S&P 500 Composite’s increase of 7.
GJT PGR AXS ALL NVA Y
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ALL / Allstate Corp. (The) on message board site Silicon Investor.
as of ET